Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
Semaglutide for secondary prevention of CVD in US adults with overweight or obesity but without diabetes is projected to yield meaningful health benefits. Lowering annual drug costs by 18% from $8604 to $7055-or making the current cash price available to all patients-would make semaglutide cost-effective at $120 000 per QALY gained.
Authors
- Ross Boylan
- S. F. Khan (ORCID: https://orcid.org/0000-0003-0898-9178)
- Pamela G. Coxson (ORCID: https://orcid.org/0000-0001-8254-2660)
- Kendra D. Sims (ORCID: https://orcid.org/0000-0002-6740-3002)
- Brandon Kyle Bellows (ORCID: https://orcid.org/0000-0003-1395-6047)
- Robert W Yeh
- Alexis L. Beatty (ORCID: https://orcid.org/0000-0001-8405-7386)
- Ivy Shi
- Kosuke Inoue (ORCID: https://orcid.org/0000-0001-9614-8103)
- Joanne Penko
- Andrew E. Moran
- Sérgio R. R. Decker
- Dhruv S. Kazi
- Susan Hennessy
Institutions
- Boston University (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Kyoto University (JP)
- Hospital Moinhos de Vento (BR)
- Deaconess Hospital (US)
- Columbia University (US)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1001/jamacardio.2025.5243
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.73